RecallRadar

FDA Drug recall D-1262-2020

Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx only, Manufactured by: Lupin Limited, Pith…

On 2020-05-20 the FDA classified a Class III recall of Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx only, Manufactured by: Lupin Limited, Pith… by The Harvard Drug Group, citing failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1262-2020
ClassificationClass III
Statusterminated
Initiated2020-04-24
Published2020-05-20
Last updated2026-09-13 11:52 UTC
CompanyThe Harvard Drug Group
DistributionAL, FL, IA, NY, OH, TX

Product

Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, India; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 47152 USA. NDC: 0904-6735-61

Reason

Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.

Identifiers

ndc0904-6734-61
ndc0904-6736-61
ndc0904-6737-61
ndc0904-6735-61
code_infoLot #: M02199D, M02246D, Exp 5/2020

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1262-2020%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.